TOLBUTAMIDE
LOE ApproachingNDAORALTABLET
Approved
Jul 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tolbutamide is an oral first-generation sulfonylurea approved in 1974 for type 2 diabetes management. It lowers blood glucose by stimulating insulin secretion from pancreatic beta cells. This legacy agent is no longer commonly prescribed due to the emergence of safer, more effective diabetes therapies.
LOE Approaching
Declining
This product is in terminal decline with minimal commercial team investment; roles are primarily focused on legacy account management and regulatory maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
Started Nov 2021
12 enrolled
Healthy Volunteers
Career Relevance
Tolbutamide offers minimal career opportunity; any role linked to this product would be focused on compliance, legacy account servicing, and regulatory maintenance rather than commercial growth or innovation. This assignment signals a non-core portfolio placement and limited advancement potential.
Medical Science Liaison (legacy support)
Worked on TOLBUTAMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.